Adaptive human immunity drives remyelination in a mouse model of demyelination
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
One major challenge in multiple sclerosis is to understand the cellular and molecular mechanisms leading to disease severity progression. The recently demonstrated correlation between disease severity and remyelination emphasizes the importance of identifying factors leading to a favourable outcome. Why remyelination fails or succeeds in multiple sclerosis patients remains largely unknown, mainly because remyelination has never been studied within a humanized pathological context that would recapitulate major events in plaque formation such as infiltration of inflammatory cells. Therefore, we developed a new paradigm by grafting healthy donor or multiple sclerosis patient lymphocytes in the demyelinated lesion of nude mice spinal cord. We show that lymphocytes play a major role in remyelination whose efficacy is significantly decreased in mice grafted with multiple sclerosis lymphocytes compared to those grafted with healthy donors lymphocytes. Mechanistically, we demonstrated in vitro that lymphocyte-derived mediators influenced differentiation of oligodendrocyte precursor cells through a crosstalk with microglial cells. Among mice grafted with lymphocytes from different patients, we observed diverse remyelination patterns reproducing for the first time the heterogeneity observed in multiple sclerosis patients. Comparing lymphocyte secretory profile from patients exhibiting high and low remyelination ability, we identified novel molecules involved in oligodendrocyte precursor cell differentiation and validated CCL19 as a target to improve remyelination. Specifically, exogenous CCL19 abolished oligodendrocyte precursor cell differentiation observed in patients with high remyelination pattern. Multiple sclerosis lymphocytes exhibit intrinsic capacities to coordinate myelin repair and further investigation on patients with high remyelination capacities will provide new pro-regenerative strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777
CCR7 and its ligands: balancing immunity and tolerance
Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410 · cited 1×
“…à la Recherche sur la Sclérose en Plaques (ARSEP), Association française contre les Myopathies (AFM), the program ‘Investissements d’Avenir’ ANR-10-IAIHU-06 and ‘Translational Research Infrastructure for Biotherapies in Neurosciences’ ANR-11-INBS-0011– NeurATRIS and ANR-10-INBS-0101 BIOBANQUES.”
BackgroundPremyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 1×
“In the last decade, the cause of the failure of remyelination in some patients has been debated: whether it results from a defect of OPC recruitment (Wolswijk, 2002; Boyd et al., 2013), a decrease of OPC differentiation (Chang et al., 2002), or both (Sim et al., 2002).”
BackgroundButovsky, O., Ziv, Y., Schwartz, A., Landa, G., Talpalar, A. E., Pluchino, S., Martino, G., & Schwartz, M. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.10.006 · Cited by 923
Wolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status
Vogel, D. Y., Vereyken, E. J., Glim, J. E., Heijnen, P. D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C. E., van Horssen, J., & Dijkstra, C. D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-35 · Cited by 479 · cited 1×
“This result confirmed post-mortem tissue studies on multiple sclerosis plaques, which reported that a majority of MIGs and macrophages present in chronically activated lesions display a pro-inflammatory phenotype (Koning et al., 2007; Vogel et al., 2013).”
ResultKotter, M. R., Setzu, A., Sim, F. J., Van Rooijen, N., & Franklin, R. J. M. (2001) · Glia · doi:10.1002/glia.1085 · Cited by 385 · cited 3×
“Indeed, depletion of innate and adaptive immune cells (Kotter et al., 2001; Bieber et al., 2003) leads to a decrease of remyelination efficacy in animal models of focal demyelination.”
BackgroundKotter, M. R., Zhao, C., van Rooijen, N., & Franklin, R. J. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.019 · Cited by 331
Butovsky, O. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26836 · Cited by 261 · cited 4×
“At least two main activated states exist: (i) classically activated (or M1) after exposition to the pro-inflammatory cytokines IFN- ; and (ii) alternatively activated (or M2) after exposure to IL-4 (Butovsky et al., 2006).”
BackgroundInfluential
Cited by
Remyelination in multiple sclerosis: From basic science to clinical translation
Lubetzki, C., Zalc, B., Williams, A., Stadelmann, C., & Stankoff, B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30140-x · Cited by 350
Self-citationRemyelination therapies: a new direction and challenge in multiple sclerosis
Plemel, J. R., Liu, W.-Q., & Yong, V. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.115 · Cited by 281
CNS remyelination and inflammation: From basic mechanisms to therapeutic opportunities
Franklin, R. J. M., & Simons, M. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.023 · Cited by 184
Positron emission tomography in multiple sclerosis - straight to the target
Bodini, B., Tonietto, M., Airas, L., & Stankoff, B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00537-1 · Cited by 74
Self-citationMozafari, S., Starost, L., Manot-Saillet, B., Garcia-Diaz, B., Xu, Y. K. T., Roussel, D., Levy, M. J. F., Ottoboni, L., Kim, K.-P., Schöler, H. R., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc6983 · Cited by 45
Metadata
- Authors
- El Behi, M., Sanson, C., Bachelin, C., Guillot-Noël, L., Fransson, J., Stankoff, B., Maillart, E., Sarrazin, N., Guillemot, V., Abdi, H., Cournu-Rebeix, I., Fontaine, B., & Zujovic, V.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-22
- Volume
- 140
- Issue
- 4
- Pages
- 967-980
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2598298647
- Cited by
- 67
- References
- 13
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptive human immunity drives remyelination in a mouse model of demyelination. https://app.cochat.ai/papers/10.1093/brain/awx008
- The paper
- El Behi, M., Sanson, C., Bachelin, C., Guillot-Noël, L., Fransson, J., Stankoff, B., Maillart, E., Sarrazin, N., Guillemot, V., Abdi, H., Cournu-Rebeix, I., Fontaine, B., & Zujovic, V. (2017). Adaptive human immunity drives remyelination in a mouse model of demyelination. Brain. https://doi.org/10.1093/brain/awx008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.